European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The prognosis of metastatic invasive epithelial ovarian tumor is poor, with a five-year survival rate under 20%. The author reports the case of a 71-year-old woman, diagnosed at the age of 65 years, with a serous papillary ovarian carcinoma with diffuse peritoneal carcinomatosis. She received four courses of neoadjuvant carboplatin plus paclitaxel chemotherapy, then underwent debulking surgery, followed by three courses of chemotherapy. Seventeen months later, diffuse metastases appeared. The patient received six cycles of carboplatin plus paclitaxel chemotherapy and obtained complete response. Ten months later, carboplatin plus gemcitabine plus bevacizumab were administered for a new relapse, followed by bevacizumab maintenance. After 28 months of bevacizumab treatment, the anti-VEGF therapy was stopped, because of proteinuria and renal failure. The patient is under hormonal therapy and has stable disease.